American Society of Hirudotherapy

Serum metabolomic profiles reveal the impact of BuZangTongLuo formula on metabolic pathways in diabetic mice with hindlimb ischemia

Research article published in Journal of ethnopharmacology (2020)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomics & ProteomicsClinical LiteratureZheng J et al. · Journal of ethnopharmacology, 2020

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: BuZangTongLuo Formula (BZTLF) was the decoction of eight traditional Chinese medicines including Astragalus membranaceus, Dioscorea opposita, Salvia miltiorrhiza, Scrophularia ningpoensis, Ophiopogon japonicus, Panax ginseng, Fritillariae cirrhosae and Whitmania pigra. This formula has been used as an effective remedy for treatment of diabetic ischemia clinically. AIM OF THE STUDY: In previous study, we have reported the therapeutic effect of BZTLF on diabetic vascular dysfunction. However, it remains obscure about the role of metabolic pathways in BZTLF-initiated improvement on hindlimb ischemia. MATERIALS AND METHODS: Diabetic mice with hindlimb ischemia were orally administrated with BZTLF by gavage. The serum samples were prepared for untargeted metabolomic analysis by ultra-performance liquid chromatography-mass spectrometer. The metabolic network was built by integrating metabolite data with the Gene Expression Omnibus (GEO) dataset (GSE3313). Further, quantitative PCR was used to confirm the key target genes. RESULTS: BZTLF treatment remarkably led to the reversal of changed metabolite levels in serum of diabetic mice with hindlimb ischemia, which mainly derived from bacteria, plant and signaling molecules. Also, BZTLF reshaped the metabolic pathways, especially those responsible for metabolism of lipid, gluthanine and tryptophan. In addition, BZTLF led to the reduction of lysophosphatidic acids (LPAs) and increment of triglycerides (TGs) conjugation with non-saturated fatty acids in serum. BZTLF significantly restored the down-regulation of vascular endothelial growth factor receptor 2 (VEGFR2) and endothelial nitric oxide synthase (eNOS) or the up-regulation of interleukin 4-induced 1 (IL4I1) and cytochrome P450 family 1 subfamily B member 1 (CYP1B1) at mRNA level, which were key regulatory genes located in metabolic pathways of glutamate and tryptophan. CONCLUSIONS: BZTLF improved hindlimb ischemia in diabetic mice by the positive regulation of metabolome changes in serum.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsChromatography, High Pressure LiquidDiabetes Mellitus, ExperimentalDrugs, Chinese HerbalHindlimbIschemiaMaleMass SpectrometryMetabolomeMetabolomicsMiceMice, Inbred C57BL

Summary

The traditional formula BuZangTongLuo, which contains Whitmania pigra, was given to diabetic mice with hindlimb ischemia and reversed altered serum metabolites, restored VEGFR2 and eNOS expression, and reduced lysophosphatidic acid levels.

Why This Matters for Hirudotherapy

This study examined how BuZangTongLuo Formula (BZTLF) — a decoction of eight traditional Chinese medicines including the leech Whitmania pigra — affects serum metabolomic profiles in diabetic mice with hindlimb ischemia, reporting that treatment reversed altered metabolite levels and reshaped pathways of lipid, gluthanine, and tryptophan metabolism, with restoration of VEGFR2 and eNOS mRNA expression. W. pigra is a leech species, and the study addresses ischemic vascular dysfunction; however, the formula is multi-component, so the leech ingredient's individual contribution cannot be isolated from these data. This is a preclinical mouse metabolomics study reporting associations, not clinical proof of efficacy, and the leech component was not tested independently.

Citation

Reference (Vancouver style)

Zheng J, Guo Y, Hu B, Zhu L, Yang Y, Li S, et al. Serum metabolomic profiles reveal the impact of BuZangTongLuo formula on metabolic pathways in diabetic mice with hindlimb ischemia. J Ethnopharmacol. 2020;258:112928. doi:10.1016/j.jep.2020.112928. PMID: 32371144

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.